csirt@kutim:~/threat-intel/cve/CVE-2026-76359

Katalog CVE

CVSS 6.5 · Medium EPSS 0,52%

Kerentanan Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') pada splunk soar. Skor CVSS 3.1 6.5 (Medium) menurut cisco.com.

Deskripsi (NVD)

In Splunk SOAR versions below 8.6.0, a user who holds the Administrator role could use path traversal in the Universal Forwarder installer's archive extraction to write files outside the intended installation directory. The vulnerability is possible because the Universal Forwarder credentials-package extraction workflow does not verify that each archive member remains within the intended destination before extraction. For more information see Manage roles and permissions in Splunk SOAR (On-premises) (https://help.splunk.com/en/splunk-soar/soar-on-premises/administer-soar-on-premises/8.5.0/manage-your-splunk-soar-on-premises-users-and-accounts/manage-roles-and-permissions-in-splunk-soar-on-premises) and Configure forwarders to send SOAR data to your Splunk deployment (https://help.splunk.com/en/splunk-soar/soar-on-premises/administer-soar-on-premises/8.5.0/configure-administration-settings-in-splunk-soar-on-premises/configure-forwarders-to-send-soar-data-to-your-splunk-deployment) in the Splunk documentation.

Rincian

Terbit di NVD
19 Agustus 2026
Terakhir diubah
21 Agustus 2026
Status NVD
Analyzed
CVSS 3.1
6.5 (Medium), sumber cisco.com
CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:N/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-22: Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal')
EPSS (30 hari)
0,52% peluang dieksploitasi; lebih tinggi dari 42,3% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
splunk soar Semua versi sebelum 8.6.0

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.